About OCUMENSION-B Company

We are a Chinese ophthalmology platform company dedicated to identifying, developing and commercializing first-of-its-kind or best-in-class ophthalmic treatments. Our vision is to provide world-class overall pharmaceutical solutions to meet the huge demand gap in ophthalmology in China. We believe our ophthalmology platform with a clear first-mover advantage will give us a leading position in the Chinese ophthalmology industry. With our platform, we have built on a comprehensive, innovative and proven ophthalmic drug portfolio that has been strategically designed. As of the date of this report, we have 18 drug assets covering all major anterior and posterior eye conditions. We have five major drug candidates under phase III clinical trial development in China, and we believe that, if approved, these drug candidates will likely be first-in-class or best-in-class, and show significant short-term profit potential as early as 2022. Our product portfolio includes 3 of 10 ophthalmic drugs approved by the FDA since 2015 but have not been marketed in China using any process. Additionally, our product portfolio includes three medications that are at or near commercialization stage. The table below provides an overview of our product portfolio and the status of each drug asset as of the date of this report.